Congress trades
Jazz Pharmaceuticals plc (JAZZ)
Free on iOS and Android.
About Jazz Pharmaceuticals plc
from the company's filings and listing, as of Oct 25, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Renee D. Gala
- Employees
- 2,890
- Listed since
- Jun 1, 2007
- Market value
- $13.9B
- Price to earnings (12 mo)
- 14.1
- Net income per share, as reported (12 mo)
- $14.89
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 2, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 3, 2026 | $5.71 | $6.18 | $1.2B | $1.1B | EPS missRevenue beat |
| Q1 FY2026reported May 5, 2026 | $6.34 | $4.64 | $1.1B | $978.7M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 24, 2026 | $6.64 | $6.52 | $1.2B | $1.2B | EPS beatRevenue beat |
| Q3 FY2025reported Nov 5, 2025 | $8.13 | $5.95 | $1.1B | $1.1B | EPS beatRevenue in line |
| Q2 FY2025reported Aug 5, 2025 | -$8.25 | -$6.12 | $1.0B | $1.0B | EPS missRevenue in line |
| Q1 FY2025reported May 6, 2025 | $1.68 | $4.51 | $897.8M | $1.1B | EPS missRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Jun 8, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Renee D. GalaPresident, CEO and Director | $1.0M | $16.1M | $2.0M | $19.2M |
| Robert Iannone, M.D., M.S.C.EExecutive Vice President, Global Head of R&D | $793K | $7.0M | $865K | $8.7M |
| Philip L. JohnsonExecutive Vice President and CFO | $741K | $6.0M | $756K | $7.5M |
| Neena M. PatilExecutive Vice President and Chief Legal Officer | $715K | $4.8M | $740K | $6.3M |
| Samantha PearceExecutive Vice President, Chief Commercial Officer | $696K | $4.7M | $721K | $6.1M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $1.4B | 5,968,603 | +6.7% | 9.44% |
| FMR LLC | $1.1B | 4,609,326 | +102.5% | 7.29% |
| Vanguard Portfolio Management LLC | $731.6M | 3,036,213 | +1.8% | 4.80% |
| Vanguard Capital Management LLC | $657.8M | 2,729,650 | +3.1% | 4.32% |
| Capital World Investors | $650.0M | 2,697,610 | +0.9% | 4.27% |
| LSV Asset Management | $548.2M | 2,275,145 | -4.7% | 3.60% |
| Franklin Templeton Inc | $491.6M | 2,040,250 | +4.2% | 3.23% |
| State Street Corp | $481.9M | 1,999,816 | +5.7% | 3.16% |
| Dimensional Fund Advisors LP | $412.9M | 1,713,592 | -9.6% | 2.71% |
| Fuller & Thaler Asset Management, Inc. | $394.8M | 1,638,544 | -2.2% | 2.59% |
| Bank of New York Mellon Corp | $380.3M | 1,578,013 | -6.0% | 2.50% |
| AQR Capital Management LLCCliff Asness | $359.9M | 1,522,568 | +13.8% | 2.41% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in JAZZ
13 disclosures of 13 on record · median 24d of the 45 allowedSince the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Daniel S. Goldman | Stock | Sale | $15,001 - $50,000 | n/a | Jul 12, 2023 | Aug 13, 2023 | 32d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | n/a | May 19, 2023 | Jun 12, 2023 | 24d |
| Daniel S. Goldman | Stock | Purchase | $15,001 - $50,000 | n/a | Mar 6, 2023 | Apr 17, 2023 | 42d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | n/a | Mar 14, 2023 | Apr 7, 2023 | 24d |
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | n/a | Jan 31, 2023 | Feb 24, 2023 | 24d |
| Thomas R. Suozzi | Stock | Sale | $1,001 - $15,000 | n/a | Sep 26, 2022 | Oct 14, 2022 | 18d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | n/a | Dec 17, 2021 | Jan 7, 2022 | 21d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | n/a | Nov 2, 2021 | Dec 7, 2021 | 35d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | n/a | Nov 9, 2021 | Dec 7, 2021 | 28d |
| Thomas R. Suozzi | Stock | Purchase | $1,001 - $15,000 | n/a | Oct 19, 2021 | Nov 5, 2021 | 17d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | n/a | Dec 17, 2018 | Jan 11, 2019 | 25d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | n/a | Jan 2, 2018 | Feb 11, 2018 | 40d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | n/a | Nov 30, 2017 | Dec 12, 2017 | 12d |
We hold no closing prices for any row shown here, so no move is shown. Not investment advice.
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in JAZZ, filterable by party, chamber, type and account.
Members of Congress reporting a position
1 member · estimate, as of Oct 24, 20261 member reports a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Jacky Rosen | Democrat · Senate | $50,001 - $100,000 | 1.0% |
Estimate, as of Oct 24, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Which members of Congress have traded JAZZ?
Daniel S. Goldman, Ro Khanna and Thomas R. Suozzi disclosed JAZZ transactions in the filings shown here.
Which members of Congress hold JAZZ?
1 member of Congress reports a position in JAZZ in the estimate we hold as of Oct 24, 2026. The estimated position belongs to Jacky Rosen. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are JAZZ trades disclosed?
Congressional disclosures took a median of 24 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 27, 2026.